- Published on 11 March 2015
Switzerland-based biopharmaceutical company Auris Medical has been granted a Chinese patent for its novel tinnitus treatment AM-101.
Auris Medical Holding AG announced on February 11 that it had recently been granted a patent by the Chinese patent office covering the use of its investigational tinnitus treatment AM-101. The patent describes methods for treatment of tinnitus induced by cochlear excitotoxicity, and in particular the use of ketamine and related compounds.
”We are very pleased by the patent grant in China, which adds substantially to our intellectual property portfolio related to AM-101”, said Thomas Meyer, company founder and Chairman and CEO of Auris Medical. “Epidemiologic studies estimate that 130 million people experience tinnitus in China, which is similar to the prevalence in other parts of the world and suggests a significant unmet medical need.”
Development of the novel treatment is based on research conducted in France at the National Institute for Health and Medical Research (INSERM). AM-101 is a small molecule acting as an N-methyl-D-aspartate (NMDA) receptor antagonist. It is being developed as a biocompatible gel for intratympanic injection. Earlier studies have shown that NMDA receptors in the cochlea play a major role in the occurrence of tinnitus following inner ear excitotoxicity. It is thought that upregulation of NMDA receptors causes abnormal excitation of auditory nerve fibers, which is perceived by affected patients as tinnitus. It is hoped that NMDA antagonists will counteract this effect.
Source: Nasdaq Global Newswire